These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 11927002

  • 1. Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
    Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y.
    Jpn J Cancer Res; 2002 Mar; 93(3):231-5. PubMed ID: 11927002
    [Abstract] [Full Text] [Related]

  • 2. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
    Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T.
    Mol Cancer Ther; 2003 Jan; 2(1):105-12. PubMed ID: 12533678
    [Abstract] [Full Text] [Related]

  • 3. Breast cancer resistance protein exports sulfated estrogens but not free estrogens.
    Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y.
    Mol Pharmacol; 2003 Sep; 64(3):610-8. PubMed ID: 12920197
    [Abstract] [Full Text] [Related]

  • 4. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
    Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y.
    Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
    [Abstract] [Full Text] [Related]

  • 5. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S.
    Int J Cancer; 2004 Jan 01; 108(1):146-51. PubMed ID: 14618629
    [Abstract] [Full Text] [Related]

  • 6. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
    Yamazaki R, Nishiyama Y, Furuta T, Hatano H, Igarashi Y, Asakawa N, Kodaira H, Takahashi H, Aiyama R, Matsuzaki T, Yagi N, Sugimoto Y.
    Mol Cancer Ther; 2011 Jul 01; 10(7):1252-63. PubMed ID: 21566063
    [Abstract] [Full Text] [Related]

  • 7. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.
    Cancer Res; 2005 Feb 15; 65(4):1541-6. PubMed ID: 15735043
    [Abstract] [Full Text] [Related]

  • 8. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
    Imai Y, Tsukahara S, Asada S, Sugimoto Y.
    Cancer Res; 2004 Jun 15; 64(12):4346-52. PubMed ID: 15205350
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
    Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T, Bates SE.
    Cancer Res; 1999 Dec 01; 59(23):5938-46. PubMed ID: 10606239
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
    Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y.
    Cancer Sci; 2009 Sep 01; 100(9):1701-7. PubMed ID: 19493273
    [Abstract] [Full Text] [Related]

  • 15. Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S.
    Clin Cancer Res; 2003 Aug 01; 9(8):3052-7. PubMed ID: 12912956
    [Abstract] [Full Text] [Related]

  • 16. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
    Ee PL, He X, Ross DD, Beck WT.
    Mol Cancer Ther; 2004 Dec 01; 3(12):1577-83. PubMed ID: 15634651
    [Abstract] [Full Text] [Related]

  • 17. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y.
    Oncol Rep; 2012 Jun 01; 27(6):1703-9. PubMed ID: 22426819
    [Abstract] [Full Text] [Related]

  • 18. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
    Imai Y, Ishikawa E, Asada S, Sugimoto Y.
    Cancer Res; 2005 Jan 15; 65(2):596-604. PubMed ID: 15695404
    [Abstract] [Full Text] [Related]

  • 19. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
    Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y.
    Int J Cancer; 2003 Dec 10; 107(5):757-63. PubMed ID: 14566825
    [Abstract] [Full Text] [Related]

  • 20. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S.
    Cancer Chemother Pharmacol; 2006 Nov 10; 58(5):594-600. PubMed ID: 16520985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.